FDV250117P29000
- 0.00
- 0.000.00%
FEDERATED HERMES U.S. STRATEGIC DIVIDEND ETF Newsroom
A strong response to the 'Trump tariff threat'! Canada’s Energy Minister: The USA cannot find alternatives at all.
① The Canadian Minister of Energy, Jonathan Wilkinson, stated that Trump's claim that the USA does not need anything from Canada is "completely wrong." ② Wilkinson mentioned that the USA finds it difficult to find alternatives to Canadian Crude Oil Product, Uranium, and potash, and warned that trade retaliation measures, including export taxes, may be taken.
S&P 500 Positive for 'First Five Days,' Huang Sees Decades till Quantum | Wall Street Today
Alger Launches Russell Innovation ETF To Capitalize On Emerging Innovators
Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus
Oak Tree Capital's Marks: New things are prone to bubbles, currently private equity buying S&P 500, with a 10-year yield of only ±2%.
Max recently released a memorandum titled "Revisiting the Bubble," stating that investors are currently betting on the leading high-tech companies to maintain their dominance. However, he believes that it is not easy to stay ahead, as new technologies and competitors can surpass existing market leaders at any time. When people assume that "things can only get better" and Buy based on that, the impact of negative news can be particularly severe. He specifically pointed out the frenzy over AI and how this positive sentiment may spread to other Technology sectors.
Chevron Sees up to $8B in Free Cash Flow Growth Next Year, CEO Says
Wednesday Market Falls, Quantum Computing Pulls Back Hard on Treasury Yield Crunch | Live Stock
Top S&P 500 SA Quant Rated Stocks to Start 2025: UAL, WFC, GM, and More
Merck Downgraded by Truist to Hold Over Growth Concerns
Shake Shack, Morgan Stanley, Synovus Financial And A Communication Services Stock On CNBC's 'Final Trades'
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Compugen Announced That The First Patient Was Dosed In A Phase 1 Clinical Trial With Com503, A Potential First-in-class Antibody Against Il-18 Binding Protein Licensed By Compugen To Gilead
Amgen Analyst Ratings
Bristol-Myers Squibb Analyst Ratings
Yield Curve Normalization, Cheap Valuation, EPS Growth To Boost Banks In 2025: Truist Initiates Coverage On These 14 Regional Names
Tuesday Market Pulls Back After Nvidia All Time High | Wall Street Today
Beyond The Numbers: 13 Analysts Discuss PNC Finl Servs Gr Stock
Looking Into Gilead Sciences's Recent Short Interest
Market Whales and Their Recent Bets on TGT Options